Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.

Stereotaxis received FDA clearance for a diagnostic catheter and utilizes Genesis robotic navigation systems.

2 reports, 2 independent Updated Jul 29
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Stereotaxis received FDA clearance for a diagnostic catheter and utilizes Genesis robotic navigation systems.

Who's involved

What this event is mainly about
StereotaxisFDAGenesis

Keep exploring

Part of

Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market. All 2 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Coverage

Newest first; wire copies grouped
  • Medical Device NetworkStereotaxis wins FDA clearance for diagnostic mapping catheter Stereotaxis has received US Food and Drug Administration (FDA) clearance for MAGiC Sweep, an electrophysiology (EP) catheter. Shares in
  • GlobeNewswireStereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally